Etanercept

Etanercept, a dimeric fusion protein that binds TNF, acts as a TNF inhibitor. Etanercept competitively inhibits the binding of both TNF-α and TNF-β to cell surface TNF receptors, rendering TNF biologically inactive. Etanercept shows efficacy against rheumatoid arthritis, juvenile idiopathic arthritis, and plaque psoriasis[1][2][3].

Product Specifications

CAS Number

[185243-69-0]

UNSPSC

12352203

Hazard Statement

H302, H315, H319, H335

Target

Bacterial; TNF Receptor

Type

Inhibitory Antibodies

Related Pathways

Anti-infection; Apoptosis

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cancer

Assay Protocol

https://www.medchemexpress.com/Etanercept.html

Purity

99.20

Solubility

H2O

Smiles

[Etanercept]

Molecular Weight

(102.5 kDa)

Precautions

H302, H315, H319, H335

References & Citations

[1]Goffe B, et al. Etanercept: An overview. J Am Acad Dermatol. 2003;49 (2 Suppl) :S105-S111.|[2]Goldenberg MM. Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. Clin Ther. 1999;21 (1) :75-2.|[3]Totoson P, et al. Etanercept improves endothelial function via pleiotropic effects in rat adjuvant-induced arthritis. Rheumatology (Oxford) . 2016;55 (7) :1308-1317.|[4]Haraoui B, et al. Etanercept in the treatment of rheumatoid arthritis. Ther Clin Risk Manag. 2007;3 (1) :99-105.